Applications open for Babraham’s 2021/2022 accelerator

Accelerate@Babraham, the bio-entrepreneurial incubator initiative founded and developed by Babraham Research Campus, is inviting applications for its 2021-22 cohort.

The five-month programme, which has been consistently supported by key industry and investor organisations, starts in September.

The five selected ventures will receive five months exploring and developing their science in the company of an unrivalled network of strategic partners, mentors, experts, and investors. Access to free lab space and £10,000 non-dilutive funding completes the package.

The closing date for applications is Wednesday, June 30. A competitive and rigorous selection process culminates in a fast-paced pitch-final on July 15, to determine which five companies make it through.

Karolina Zapadka, head of Accelerate@Babraham, said: “Further to launching Accelerate@Babraham in 2018, we have supported 15 companies, delivered over 130 bespoke training sessions, facilitated over 330 hours of round-table seminars and discussions, and made a multitude of personal introductions to investors and key opinion leaders across the board. The result of which is an alumni which has raised a total investment of £12.5m to date and made connections that will have career-long value.

“What sets Accelerate@Babraham apart is the quality of our network of strategic partners and supporters and the willingness of world-class scientists, business experts and investors to give their time freely to help us provide a springboard for these early-stage enterprises.

“If you are an early-stage life science start-up with a great idea and want to test your science, this is a once-in-a-lifetime opportunity to do it at one of the best-connected campus communities in Europe.”

Accelerate@Babraham is supported by a core group of strategic supporters – AstraZeneca, Eisai, LifeArc, Mundipharma, and Kidney Research UK.

Details here.